Sector News

Incoming St. Jude medical president and CEO Mike Rousseau announces executive leadership team

September 15, 2015
Life sciences

(BUSINESS WIRE) – St. Jude Medical, Inc. today announced the new executive leadership team that incoming President and Chief Executive Officer (CEO) Michael T. Rousseau has chosen to lead the organization into the next phase of growth and innovation. Effective Jan. 1, 2016, the new team alignment leverages the Company’s deep bench of talent and ensures the continuity of key leadership positions within St. Jude Medical.

“We are fortunate to have an executive team that’s uniquely qualified to continue St. Jude Medical’s growth story,” Rousseau said. “This is a remarkable team with a diverse set of experiences and a proven track record that will allow us to continue to transform and diversify the way we develop medical technologies in order to improve the care for patients around the world. Over the past several years, our executive team has made significant contributions to the business and shares in the excitement of the future of St. Jude Medical.”

The executive leadership team will include a new structure intended to drive organizational effectiveness and maximize the depth of experience of St. Jude Medical leaders. No changes, other than one addition, will be made to the current roster of St. Jude Medical Executive Officers. The following officers will report to Rousseau, effective Jan. 1, 2016:

Source: St. Jude Medical

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend